Rating To Observe: HSBC Reiterates Astrazeneca (LON:AZN) As Hold; Has Target Price Of GBX 4700.00

November 23, 2016 - By Peter Kolinski

Astrazeneca (LON:AZN) Rating

In an analyst note revealed to investors and clients on Wednesday morning, Astrazeneca (LON:AZN) stock Hold was kept by Analysts at HSBC. They currently have a GBX 4700.00 target price per share on the stock. HSBC’s target price per share would suggest a potential upside of 12.40% from the company’s previous close.

AstraZeneca plc (LON:AZN) Ratings Coverage

Out of 30 analysts covering AstraZeneca PLC (LON:AZN), 13 rate it a “Buy”, 4 “Sell”, while 13 “Hold”. This means 43% are positive. GBX 7000 is the highest target while GBX 3700 is the lowest. The GBX 4922.09 average target is 18.58% above today’s (GBX 4151) stock price. AstraZeneca PLC has been the topic of 340 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating given on Thursday, December 10 by Bernstein. The firm earned “Hold” rating on Tuesday, October 4 by Liberum Capital. BNP Paribas maintained the shares of AZN in a report on Friday, January 8 with “Outperform” rating. As per Monday, November 9, the company rating was maintained by BNP Paribas. The firm has “Market Perform” rating given on Thursday, September 3 by Bernstein. The stock of AstraZeneca plc (LON:AZN) has “Hold” rating given on Wednesday, October 26 by Liberum Capital. The rating was maintained by Deutsche Bank on Tuesday, May 31 with “Buy”. Deutsche Bank maintained the shares of AZN in a report on Monday, February 8 with “Buy” rating. The firm has “Buy” rating given on Friday, August 21 by Liberum Capital. The stock of AstraZeneca plc (LON:AZN) has “Neutral” rating given on Wednesday, November 2 by JP Morgan.

About 1.33 million shares traded hands. AstraZeneca plc (LON:AZN) has risen 2.98% since April 25, 2016 and is uptrending. It has underperformed by 2.35% the S&P500.

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of 52.80 billion GBP. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 26.47 P/E ratio. The Firm has its activities in over 100 countries.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (LON:AZN) news was published by Streetinsider.com which published an article titled: “Form 6-K ASTRAZENECA PLC For: Nov 22” on November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>